MK-2870 is an investigational medication being studied for its potential to treat metastatic non-small cell lung cancer. It is being tested in combination with another medication to see if it can improve outcomes for patients with this type of cancer.

Pembrolizumab is a medication used to treat various types of cancer, including non-small cell lung cancer. It works by helping the immune system recognize and attack cancer cells. In this study, it is being used both alone and in combination with MK-2870 to determine the best treatment approach for patients with a specific type of lung cancer.

Metastatic Non-Small Cell Lung Cancer (NSCLC) – This is a type of lung cancer that begins in the cells lining the lungs and has spread to other parts of the body. It is the most common type of lung cancer, accounting for about 85% of cases. The disease progresses as cancer cells grow and form tumors in the lungs, which can then metastasize to other organs such as the brain, bones, or liver. Symptoms may include persistent cough, chest pain, and difficulty breathing. As the cancer advances, it can lead to more severe respiratory issues and systemic symptoms like weight loss and fatigue. The progression of the disease can vary greatly among individuals, depending on factors like the cancer’s genetic makeup and the patient’s overall health.